A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)

Olander K.W., Sato M.A., Abrams M.A., Jerkins G.W., Lu F., Dinh P., Odani-Kawabata N., Chabi A., Shams N.K.

Affiliations

University Eye Specialists, TN, Maryville, United States; East West Eye Institute, Los Angeles, CA; Abrams Eye Center, Cleveland, OH; Advancing Vision Research, TN, Nashville, United States; Santen Inc., Emeryville, CA; Santen Pharmaceutical Co., Ltd.Osaka, Japan

Related Publications

Taniguchi T.; Sharif N.A.; Ota T.; Farjo R.A.; Rausch R.

Oddone F, Tanga L, Giammaria S, Sabbatini L, Strianese A, Ferrazza M, Rossetti LM

Lamb W D.B.; Eastlake K.; Luis J.; Sharif N.A. ; Khaw P. T.; Limb G. A.